Article Text

Download PDFPDF
Current 10-year atherosclerotic cardiovascular disease risk threshold for statin eligibility is cost-effective for primary prevention
  1. Joseph Yeboah
  1. Wake Forest School of Medicine, Winston-Salem, USA
  1. Correspondence to : Dr Joseph Yeboah, Wake Forest School of Medicine, Medical Center Boulevard, Winston-Salem NC 27157, USA; jyeboah{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Commentary on: OpenUrlCrossRefPubMed.


The American College of Cardiology American Heart Association (ACC/AHA) cholesterol guidelines replaced the National Cholesterol Education Program Adult Treatment Panel III (NCEP/ATP III) in 2013,1 a change that was accompanied by significant controversy.2 Notable among the criticisms was that the pooled cohort equations (PCE) overestimates risk and coupled with the relatively lenient risk threshold (10-year PCE ≥7.5%), would unnecessarily increase statin eligibility in the USA. The risk-benefit ratio and cost-effectiveness of this new approach, specifically for primary prevention, was questioned since statins (in addition to preventing cardiovascular disease (CVD) events) have known significant side effects. Pandya and colleagues examine the cost-effectiveness of 10-year risk thresholds for initiation of …

View Full Text


  • Competing interests None declared.

  • Provenance and peer review Commissioned; internally peer reviewed.